Literature DB >> 23972707

Systemic treatment options for untreated patients with metastatic clear cell renal cancer.

Ana M Molina1, Robert J Motzer, Daniel Y Heng.   

Abstract

The introduction of therapy targeting vascular endothelial growth factor (VEGF) and the mammalian target of rapomycin (mTOR) has significantly improved the outcome of patients with metastatic renal cancer. In this article a comprehensive overview of treatment choices for previously untreated patients with metastatic disease is given. Both established and emerging therapeutic options are discussed, as are prognostic factors predicting outcome.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23972707     DOI： 10.1053/j.seminoncol.2013.05.013

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  11 in total

Review 1.  Novel and emerging targeted-based cancer therapy agents and methods.

Authors:  Mohammad Hojjat-Farsangi
Journal:  Tumour Biol       Date:  2015-02-09

2.  Kidney cancer: decreased incidence of skeletal-related events in mRCC.

Authors:  Takeshi Yuasa; Shinji Urakami
Journal:  Nat Rev Urol       Date:  2014-03-11       Impact factor: 14.432

3.  [Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib].

Authors:  C Keil; L Götze; P Olbert; R Hofmann; W A Nockher; A Hegele
Journal:  Urologe A       Date:  2015-06       Impact factor: 0.639

4.  A simple prognostic model for overall survival in metastatic renal cell carcinoma.

Authors:  Hazem I Assi; Francois Patenaude; Ethan Toumishey; Laura Ross; Mahmoud Abdelsalam; Tony Reiman
Journal:  Can Urol Assoc J       Date:  2016 Mar-Apr       Impact factor: 1.862

5.  Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication.

Authors:  Oana Draghiciu; Hans W Nijman; Baukje Nynke Hoogeboom; Tjarko Meijerhof; Toos Daemen
Journal:  Oncoimmunology       Date:  2015-01-07       Impact factor: 8.110

6.  PANDA: pathway and annotation explorer for visualizing and interpreting gene-centric data.

Authors:  Steven N Hart; Raymond M Moore; Michael T Zimmermann; Gavin R Oliver; Jan B Egan; Alan H Bryce; Jean-Pierre A Kocher
Journal:  PeerJ       Date:  2015-05-19       Impact factor: 2.984

7.  The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.

Authors:  Ki Cheong Park; Jun Hyeok Heo; Jeong Yong Jeon; Hye Ji Choi; A Ra Jo; Seung Won Kim; Ho Jeong Kwon; Sung Joon Hong; Kyung Seok Han
Journal:  BMC Cancer       Date:  2015-01-23       Impact factor: 4.430

8.  The world of targeted therapies in kidney cancers: pitfalls, tips and tricks.

Authors:  Alexis Vallard; Jane-Chloé Trone; Julien Langrand-Escure; Sophie Espenel; Jean-Baptiste Guy; Chloé Rancoule; Yaoxiong Xia; Anis El Meddeb Hamrouni; Majed Ben Mrad; Nicolas Magné
Journal:  Onco Targets Ther       Date:  2017-03-03       Impact factor: 4.147

Review 9.  Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy.

Authors:  Vyshak Alva Venur; Monika Joshi; Kenneth G Nepple; Yousef Zakharia
Journal:  Drug Des Devel Ther       Date:  2017-04-11       Impact factor: 4.162

10.  A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development.

Authors:  Oana Draghiciu; Annemarie Boerma; Baukje Nynke Hoogeboom; Hans W Nijman; Toos Daemen
Journal:  Oncoimmunology       Date:  2015-05-27       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.